P220029/S003: Optilume BPH Catheter System
FDA’s recorded scope: Approval of the revised protocol for the post-approval study (PAS)
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 2 FDA records to the applicant name Urotronic, Inc.. 1 entry is a PMA supplement. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Dec 12, 2025 to Dec 15, 2025. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QXB appears in 2 of the 2 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P220029, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 2495 Xenium Ln., Minneapolis, MN, 55449. Recorded on P220029/S003, decision dated Dec 15, 2025.
Drug coated prostatic dilation catheter for benign prostatic hyperplasia.
FDA’s recorded scope: Approval of the revised protocol for the post-approval study (PAS)
FDA’s recorded scope: a change of an additional pre-dilation catheter supplier manufacturing site
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.